About Abzena
Abzena is a company based in Cambridge (United Kingdom) founded in 2001 was acquired by Welsh, Carson, Anderson & Stowe in August 2018. Abzena has raised $67.11 million across 11 funding rounds from investors including Mercia, Welsh, Carson, Anderson & Stowe and YFM Equity Partners. The company has 306 employees as of December 31, 2020. Abzena has completed 1 acquisition, including PacificGMP. Abzena offers products and services including Antibody Discovery, Bioconjugate Development, Cell Line Development, and Formulation Development. Abzena operates in a competitive market with competitors including Syngene, Patheon, Piramal Group, Maravai Life Sciences and LakePharma, among others.
- Headquarter Cambridge, United Kingdom
- Employees 306 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Abzena Limited
- Date of Incorporation 25 Mar, 2014
- Jurisdiction CAMBRIDGE
-
Annual Revenue
$22.12 M (USD)119as on Dec 31, 2016
-
Net Profit
-$41.47 M (USD)0as on Dec 31, 2019
-
EBITDA
Not available
-
Total Equity Funding
$67.11 M (USD)
in 11 rounds
-
Latest Funding Round
$65 M (USD), Post-IPO
Mar 31, 2022
-
Investors
Mercia
& 8 more
-
Employee Count
306
as on Dec 31, 2020
- Investments & Acquisitions
-
Acquired by
Welsh, Carson, Anderson & Stowe
(Aug 16, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Abzena
Abzena offers a comprehensive portfolio of products and services, including Antibody Discovery, Bioconjugate Development, Cell Line Development, and Formulation Development.
Service for identifying high-affinity antibodies with desired activity.
Development of ADCs and related conjugates for targeted therapies.
Generation of cell lines for biologics production and GMP processes.
Optimization of formulations for monoclonal antibodies and conjugates.
People of Abzena
Unlock access to complete
Funding Insights of Abzena
Abzena has successfully raised a total of $67.11M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $65 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Abzena
Abzena has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, Welsh, Carson, Anderson & Stowe and YFM Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare and technology sectors are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
Biospring is engaged in partnering with pharma services businesses.
|
Locked | Locked | Locked | |
|
Investments in startups are focused on Europe and the US.
|
Locked | Locked | Locked |
Investor details for Abzena
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abzena
Abzena has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include PacificGMP.
Investment portfolio details for Abzena
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Contract manufacturing in cGMP and non-GMP biologics is provided.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Abzena
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Abzena
Detailed financials for Abzena
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abzena Comparisons
Peer comparison for Abzena
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Abzena
Abzena operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Syngene, Patheon, Piramal Group, Maravai Life Sciences and LakePharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of contract research and manufacturing services for both small molecules and biologics
|
|
| Locked | Locked | Locked |
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry
|
|
| Locked | Locked | Locked |
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
|
|
| Locked | Locked | Locked |
Provides enabling tools and services in the life sciences research and bio-production industries
|
|
| Locked | Locked | Locked |
Provider of drug discovery on molecular biology, viral vectors and cell & protein engineering
|
Detailed competitors of Abzena
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abzena
Complete news archive for Abzena
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abzena
Abzena was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Abzena is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Jonathan Goldman is the current CEO of Abzena.
Abzena is a funded company, having raised a total of $67.11M across 11 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Abzena is 306.
Annual revenue of Abzena is $22.12M as on Dec 31, 2016.
Abzena was founded in 2001 and is headquartered in Cambridge, United Kingdom. Operations focus on the biotechnology sector, where services in antibody discovery, cell line development, and bio analytics are delivered. Additional offerings include proprietary technologies, mammalian and bio conjugates manufacturing, peptide synthesis, analytical development, and bio assays to support pharmaceutical and research needs.
Abzena's top competitors include Syngene, Grand River Aseptic Manufacturing and Patheon.
Abzena offers Antibody Discovery, Bioconjugate Development, Cell Line Development, and Formulation Development.
Abzena has made 1 acquisition, including PacificGMP.
Abzena has 9 investors. Key investors include Mercia, Welsh, Carson, Anderson & Stowe, YFM Equity Partners, Invesco Perpetual, and Imperial Innovations.